Ligand Pharmaceuticals Incorporated (LGND) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Ligand Pharmaceuticals Incorporated  (NASDAQ: LGND)


Ligand Pharmaceuticals Incorporated's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Ligand Pharmaceuticals Incorporated's ROA in the second quarter of 2026?
Ligand Pharmaceuticals Incorporated achieved a return on average assets (ROA) of 10.86 % in its second quarter of 2026, which is below Ligand Pharmaceuticals Incorporated's average return on assets, which stands at 11.51%.

ROA has improved compared to 10.18% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 82 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 549, from total ROA ranking in the first quarter of 2026 at 684.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 129.58 % 68.77 % 88.69 % 54.8 % 9.58 %
Y / Y Net Income Change 900.78 % - - - -
Net Income (TTM) in million 197 154 124 49 -76
Return On Assets (TTM) 10.86 % 10.18 % 9.21 % 4.38 % -7.76 %
LGND's Total Ranking # 549 # 684 # 1266 # 3199 # 3480
Total Assets (TTM) in million 2,186 1,532 2,067 1,480 952
Seq. Total Assets Change 42.67 % -25.9 % 39.74 % 55.39 % 4.88 %
Seq. Net Income Change - - -61.81 % 2319.5 % -

LGND's 5 Years Annual ROA >> Back to LGND Management Effectiveness >> Compare LGND ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 36
Sector # 83
Overall # 506

Return On Assets Statistics
High Average Low
69.6 %
11.51 %
-14.46 %
(Sep 30 2015)   (Mar 31 2025)





Financial Statements
Ligand Pharmaceuticals Incorporated's Assets $ 2,186 million LGND's Balance sheet
Ligand Pharmaceuticals Incorporated's Income $ 49 million Quarterly LGND's Income Statement
LGND's Income by Division See LGND's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 78.17 % -13.05 % 42.36 % -41.22 % -4.75 %
Total Assets in million 1,682 944 1,086 763 1,298
Y / Y Net Income Change - - - - -
Net Income in million 124 -4 52 -33 57
Annual Return On Assets 7.4 % -0.43 % 4.8 % -4.37 % 4.4 %

LGND's 5 Years Annual ROA >> Back to LGND Management Effectiveness >> Compare LGND ROA to its Competitors



Comment on LGND's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 7.4 % compared to prior year, due to annual net income growth of % to $124.45 million, while value of Ligand Pharmaceuticals Incorporated's overall assets grew just by 78.17 % to $1,682.09 million, compared to $1,682.09 a year before.


More Return On Assets Ratios
LGND's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LGND's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LGND's Competitors
Subscribers only: Roa for Ligand Pharmaceuticals Incorporated's Suppliers
Subscribers only: Return On Assets for LGND's Customers

You may also want to know
LGND's Roi LGND's Inventory Turnover Ratio LGND's Growth Rates LGND's Dividend Comparisons
LGND's Profitability Ratios LGND's Asset Turnover Ratio LGND's Dividend Growth
LGND's Roe LGND's Valuation Ratios LGND's Financial Strength Ratios LGND's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %
Krystal Biotech Inc   17.65 %
Chemed Corporation  17.52 %
Zoetis Inc   17.19 %
Vertex Pharmaceuticals Inc  16.88 %
Halozyme Therapeutics Inc   16.55 %
Alnylam Pharmaceuticals Inc   15.76 %
Intuitive Surgical Inc   15.63 %
Healthcare Services Group Inc   15.21 %
Inspire Medical Systems inc   15.21 %
Dexcom Inc   14.87 %
Neurocrine Biosciences Inc   14.73 %
Entera Bio Ltd   14.60 %

Date modified: 2026-09-26T07:17:25+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.